COMPANYNov 6, 2026 · 1 min read
Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate
By Benzinga Newsdesk
- li>Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1/li>li>First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3 /li>li>Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer2/li>
Share this article
Keep reading.
Trade what
you just read.
Apply the analysis on a live or demo account, same execution, no risk on demo.
Your seat at the market is ready.
Open your account in minutes, transparent pricing, fast withdrawals and support that answers.